IRWD Q2 2025 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$85M-9.7% YoY

Gross Profit

$85M100.0% margin

Operating Income

$45M53.2% margin

Net Income

$24M27.7% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+107.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$343M

Total Liabilities

$651M

Stockholders' Equity

-$308M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$94M	-9.7%
Gross Profit	$85M	$94M	-9.7%
Operating Income	$45M	$25M	+81.5%
Net Income	$24M	-$860,000	+2844.1%

Revenue Segments

Collaborative arrangements revenue

$3M67%

Royalty

$900,00021%

Collaborative arrangement, collaboration and license agreements

$428,00010%

Collaborative arrangement, other agreements

$87,0002%

Geographic Segments

North America

$86M99%

Europe and Other

$904,0001%